|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
KR20240024328A
(ko)
|
2016-11-22 |
2024-02-23 |
알로플렉스 바이오테라퓨틱스 |
동종이형 종양 세포 백신
|
|
US11185586B2
(en)
|
2016-11-22 |
2021-11-30 |
Alloplex Biotherapeutics, Inc. |
Allogeneic tumor cell vaccine
|
|
AU2018223211B2
(en)
*
|
2017-02-21 |
2025-02-27 |
Adelaide university |
T cells expressing chemokine receptors for treating cancer
|
|
EP4317422A3
(en)
|
2017-04-13 |
2024-05-01 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
AU2018254517A1
(en)
*
|
2017-04-19 |
2019-12-05 |
University Of Southern California |
Compositions and methods for treating cancer
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019025800A1
(en)
*
|
2017-08-02 |
2019-02-07 |
Autolus Limited |
CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
|
|
GB201713078D0
(en)
|
2017-08-15 |
2017-09-27 |
Adaptimmune Ltd |
T Cell Modification
|
|
AU2018329741B2
(en)
*
|
2017-09-08 |
2025-02-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
|
WO2019077037A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
|
|
WO2019118921A1
(en)
|
2017-12-14 |
2019-06-20 |
Flodesign Sonics, Inc. |
Acoustic transducer drive and controller
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
JP2021514187A
(ja)
*
|
2018-02-15 |
2021-06-10 |
ザ ナショナル インスティテュート フォー バイオテクノロジー イン ザ ネゲヴ リミテッドＴｈｅ Ｎａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎ Ｔｈｅ Ｎｅｇｅｖ Ｌｔｄ． |
キメラ抗原受容体の腫瘍環境特異的発現
|
|
CN111867598A
(zh)
*
|
2018-03-13 |
2020-10-30 |
国立大学法人大阪大学 |
肿瘤免疫赋活剂
|
|
EP3781176A4
(en)
*
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
CN108913718A
(zh)
*
|
2018-07-20 |
2018-11-30 |
苏州茂行生物科技有限公司 |
一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
|
|
CN108949825A
(zh)
*
|
2018-07-30 |
2018-12-07 |
苏州茂行生物科技有限公司 |
一种靶向her2的car-t细胞的制备方法及应用
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
CN113166778A
(zh)
*
|
2018-09-05 |
2021-07-23 |
葛兰素史克知识产权开发有限公司 |
T细胞修饰
|
|
US12097219B2
(en)
|
2018-09-10 |
2024-09-24 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CLL1 and constructs thereof
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
SG11202103317XA
(en)
|
2018-10-17 |
2021-05-28 |
Senti Biosciences Inc |
Combinatorial cancer immunotherapy
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
GB201819540D0
(en)
|
2018-11-30 |
2019-01-16 |
Adaptimmune Ltd |
T cell modification
|
|
WO2020118094A1
(en)
*
|
2018-12-06 |
2020-06-11 |
Guangdong Tcrcure Biopharma Technology Co., Ltd. |
Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
|
|
US12419913B2
(en)
|
2019-02-08 |
2025-09-23 |
Dna Twopointo, Inc. |
Modification of CAR-T cells
|
|
JP2022521486A
(ja)
*
|
2019-02-08 |
2022-04-08 |
ディーエヌエイ ツーポイント インコーポレイテッド |
トランスポゾンに基づく免疫細胞の改変
|
|
WO2020172553A1
(en)
*
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
WO2020181221A1
(en)
*
|
2019-03-07 |
2020-09-10 |
Children's Medical Center Corporation |
Targeted delivery of immune-modulating vhh and vhh-fusion protein
|
|
US20220204575A1
(en)
*
|
2019-04-23 |
2022-06-30 |
The Regents Of The University Of California |
Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
CN114787373A
(zh)
*
|
2019-07-25 |
2022-07-22 |
免疫苏醒公司 |
测量通过效应子进行的细胞介导的杀伤的方法
|
|
CN114450397A
(zh)
*
|
2019-08-01 |
2022-05-06 |
纪念斯隆-凯特琳癌症中心 |
用于改善免疫疗法的细胞及其用途
|
|
JP2022545541A
(ja)
*
|
2019-08-28 |
2022-10-27 |
センティ バイオサイエンシズ インコーポレイテッド |
組み合わせがん免疫療法
|
|
JP7831937B2
(ja)
|
2019-09-03 |
2026-03-17 |
クリエイト・メディシンズ，インコーポレーテッド |
ゲノム組込みのための方法および組成物
|
|
MX2022004772A
(es)
*
|
2019-10-22 |
2022-07-19 |
Alloplex Biotherapeutics |
Composiciones y métodos para la activación y la expansión in vitro de poblaciones de linfocitos t citolíticos en serie e inmunización pasiva de un paciente de cáncer con células tumorales asesinas.
|
|
CN115297873A
(zh)
*
|
2019-11-08 |
2022-11-04 |
梅约医学教育与研究基金会 |
利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
|
|
CN112941028A
(zh)
*
|
2019-12-09 |
2021-06-11 |
上海细胞治疗集团有限公司 |
纳米抗体基因修饰的间充质干细胞及其制备方法与应用
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
CA3164706A1
(en)
*
|
2020-01-14 |
2021-07-22 |
Jonathan David SILK |
Method of treatment of cancer or tumour
|
|
IL295896A
(en)
|
2020-02-26 |
2022-10-01 |
Biograph 55 Inc |
c19 c38 bispecific antibodies
|
|
CN115335087A
(zh)
*
|
2020-04-01 |
2022-11-11 |
南京传奇生物科技有限公司 |
用于减少同种异体细胞疗法中的移植物排斥的组合物和方法
|
|
WO2022005994A1
(en)
*
|
2020-06-29 |
2022-01-06 |
Memorial Sloan Kettering Cancer Center |
C825 expressing immune cells and diagnostic uses thereof
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
JP7849891B2
(ja)
*
|
2020-08-24 |
2026-04-22 |
シャリテ－ウニベルジテーツメディツィン ベルリン |
Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
|
|
WO2022093884A1
(en)
*
|
2020-10-27 |
2022-05-05 |
Pact Pharma, Inc. |
Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
|
|
CA3197423A1
(en)
|
2020-11-04 |
2022-05-12 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
US12234473B2
(en)
|
2020-12-31 |
2025-02-25 |
Immatics US, Inc. |
CD8 polypeptides, compositions, and methods of using thereof
|
|
EP4308133A4
(en)
|
2021-03-17 |
2025-01-22 |
Myeloid Therapeutics, Inc. |
MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2022272235A1
(en)
|
2021-05-11 |
2023-12-21 |
Create Medicines, Inc. |
Methods and compositions for genomic integration
|
|
JP2024524983A
(ja)
*
|
2021-06-24 |
2024-07-09 |
ジョージア テック リサーチ コーポレイション |
熱標的化によるｔ細胞療法の遠隔制御のための方法及び組成物
|
|
CN113789299B
(zh)
*
|
2021-10-18 |
2023-03-24 |
新鲁细胞生物科技(海南)有限公司 |
一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
|
|
EP4598553A1
(en)
*
|
2022-10-07 |
2025-08-13 |
Senti Biosciences, Inc. |
Armed chimeric receptors and methods of use thereof
|
|
WO2024107410A1
(en)
*
|
2022-11-14 |
2024-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
|
|
JP2026510999A
(ja)
|
2023-03-21 |
2026-04-10 |
バイオグラフ ５５，インク． |
Ｃｄ１９／ｃｄ３８多重特異性抗体
|
|
FI131854B1
(en)
|
2023-05-29 |
2026-01-12 |
Onni Biotechnologies Oy |
Modified natural killer cells with enhanced cytotoxic activity and greater survival
|
|
WO2025081190A1
(en)
*
|
2023-10-12 |
2025-04-17 |
Georgia Tech Research Corporation |
Image guided car t cell therapy to treat brain tumors
|